Teleflex (TFX) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Teleflex (TFX) do?
Teleflex Incorporated (TFX) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Manufactures specialized disposable instruments and catheters for critical care, surgical procedures, and cardiac surgery. It designs specialized single-use medical devices primarily for intensive care units and operating rooms. It is worth $6.48B on the market and sold $2.26B over the last year.
- Market cap
- $6.48B
- P/E ratio
- 19.9×
- Annual sales
- $2.26B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Brief updated
- Nov 18, 2026
Brands and businesses behind TFX
- Arrow: Manufactures vascular access catheters and related insertion kits for hospital critical care units.
- UroLift: Sells minimally invasive permanent implant systems used by urologists to treat enlarged prostate conditions.
- QuikClot: Produces chemically treated hemostatic gauze pads and dressings that accelerate blood clotting for trauma wounds.
- LMA: Supplies supraglottic airway management masks used by anesthesiologists during surgical procedures.
- Rusch: Sells endotracheal tubes, urinary drainage bags, and catheters to hospitals for patient care.
TFX’s flags, in plain English
Each flag is a number from Teleflex’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Wide Gross Margin
Gross margin of 65.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Growth vs Price
The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.
Stupid Cash
Can pay this year's bills 2 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Growth Cooling
Sales growth slowed to -4.7% a year over 5 years. Sales are growing more slowly than before, which makes the current share price harder to justify.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about TFX
How big is Teleflex?
Teleflex’s market cap is $6.48B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.26B: what customers paid the company over the last year, before any costs.
What is TFX’s P/E ratio?
TFX’s P/E ratio is 19.9×. Investors pay about 19.9 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with TFX?
Sales of the UroLift system face pressure from competing office-based urology treatments and changing payer reimbursement policies. That is one risk on Teleflex’s card. Its first risk flag is Growth Cooling, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Teleflex’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. TFX’s filings on SEC.gov. The Margin Monkey is research, not advice.
